2-acetylaminofluorene has been researched along with ellagic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwata, H; Mori, H; Mori, Y; Niwa, K; Tanaka, T | 1 |
| Chung, JG; Hsia, TC; Hung, CF; Lin, SS; Tyan, YS; Yang, CC; Yang, MD | 1 |
2 other study(ies) available for 2-acetylaminofluorene and ellagic acid
| Article | Year |
|---|---|
Inhibitory effect of ellagic acid on N-2-fluorenylacetamide-induced liver carcinogenesis in male ACI/N rats.
Topics: 2-Acetylaminofluorene; Animals; Benzopyrans; Body Weight; Ellagic Acid; gamma-Glutamyltransferase; Liver Neoplasms, Experimental; Male; Organ Size; Precancerous Conditions; Rats; Rats, Inbred ACI | 1988 |
Ellagic [correction of ellagica] acid inhibits arylamine N-acetyltransferase activity and DNA adduct formation in human bladder tumor cell lines (T24 and TSGH 8301).
Topics: 2-Acetylaminofluorene; 4-Aminobenzoic Acid; Antineoplastic Agents, Phytogenic; Arylamine N-Acetyltransferase; DNA Adducts; Dose-Response Relationship, Drug; Ellagic Acid; Enzyme Inhibitors; Flavonoids; Humans; Phenols; Polymers; Polyphenols; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |